Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

35.700
+0.3601.02%
Volume:103.39K
Turnover:3.65M
Market Cap:216.48B
PE:32.90
High:35.700
Open:35.700
Low:35.700
Close:35.340
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:- -
T/O Rate:0.00%
Dividend:0.49
Dividend Rate:1.38%
EPS(LYR):1.085
ROE:19.40%
ROA:9.08%
PB:4.91
PE(LYR):32.90
PS:11.67

Loading ...

Hang Seng Index Quarterly Review Boosts Industrial and Healthcare Sector Coverage; Six Stocks May Enter Southbound Trading

Stock News
·
May 25

Hang Seng Index Quarterly Review Results Announced: New Additions Include J&T Express, BeiGene, and CHALCO

Deep News
·
May 22

Hansoh Pharmaceutical Group Stock Falls 1.1% in Hong Kong

Dow Jones
·
May 22

Hansoh Pharma Clinches NMPA Breakthrough Designation for Fourth-Gen Cancer Tablet

MT Newswires Live
·
May 22

HANSOH PHARMA's Fourth-Generation EGFR Inhibitor HS-10504 Granted Breakthrough Therapy Designation for Lung Cancer

Stock News
·
May 21

Hansoh Pharma Receives NMPA Breakthrough-Therapy Designation for Fourth-Gen EGFR-TKI HS-10504

Bulletin Express
·
May 21

Hansoh Pharmaceutical - Nmpa Grants Breakthrough-Therapy Designation to Hs-10504 Tablets for Nsclc

THOMSON REUTERS
·
May 21

Johnson & Johnson says nipocalimab approved in China

Reuters
·
May 21

Hansoh Pharmaceutical Group Stock Sheds 1.1% in Hong Kong

Dow Jones
·
May 20

Hansoh Pharmaceutical Group Stock Falls 2.8% in Hong Kong

Dow Jones
·
May 18

HANSOH PHARMA Announces Appointment of New Joint Company Secretary and Authorized Representative

Stock News
·
May 15

Hansoh Pharma Reshuffles Company Secretariat: New Joint Company Secretary and Authorized Representative Appointed

Bulletin Express
·
May 15

Hansoh Pharma names Zeng Zhao joint company secretary after Lee Leong Yin resigns

Reuters
·
May 15

Hansoh Pharmaceutical Group Stock Sheds 1.3% in Hong Kong

Dow Jones
·
May 14

Hansoh Pharma Gets China Nod for Trial of Tumor Drug

MT Newswires Live
·
May 14

Hansoh Pharma Receives NMPA Green Light to Launch HS-10541 Clinical Trials for KRAS G12C Solid Tumors

Bulletin Express
·
May 13

HANSOH PHARMA's Novel Drug HS-10541 Tablets Receive Clinical Trial Approval from NMPA

Stock News
·
May 13

Hansoh Pharma wins China approval to start HS-10541 trial in KRAS G12C tumors

Reuters
·
May 13

Hansoh Pharmaceutical - Hs-10541 Tablets Obtain Clinical Trial Approval From China's Nmpa

THOMSON REUTERS
·
May 13

Hansoh Pharmaceutical Group Stock Advances 1.2% in Hong Kong

Dow Jones
·
May 11